**Key Information Document**

***Purpose:*** *This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.*

## Product

# CPR Focus Inflation - R

*Management Company: CPR Asset Management (hereinafter: "we" or the "Management Company"), a member of the Amundi Group of companies.*
*FR0013294659 - Currency: EUR*
*Management Company's website: www.cpram.com*
*Call +33 153157000 for more information.*
*The AMF ("Autorité des Marchés Financiers") is responsible for supervising CPR ASSET MANAGEMENT in relation to this Key Information Document.*
*CPR ASSET MANAGEMENT is authorised in France under number GP-01056 and regulated by the AMF.*
*Key Information Document production date: 01/09/2026.*

## What is this product?

**Type:** Units of CPR Focus Inflation, a UCITS (Undertaking for Collective Investment in Transferable Securities), established in the form of an FCP.
**Term**: The product has a duration of 99 years. The Management Company may dissolve the product by means of liquidation or merger with another product in accordance with legal requirements.
**AMF Classification ("Autorité des Marchés Financiers"):** Bonds and other international debt securities

**Objectives:** By subscribing to CPR Focus Inflation, you are investing in a bond portfolio that aims to benefit from the expected rise in inflation on the global markets (mainly the Eurozone and the United States) while hedging against a possible rate hike.

The management objective is to outperform the composite index comprised of 50% Markit iBoxx USD Breakeven 10-Year Inflation (EUR) Hedged + 50% iBoxx EUR Breakeven 10-Year Inflation France & Germany Index.

To achieve this, the management team will implement active management by purchasing inflation-indexed bonds while selling nominal rates. This hedging will be achieved through the use of derivative instruments. This strategy can also be achieved via inflation derivatives. Thus, the implicit inflation sensitivity will be controlled within a range of [+5;+15]. Implicit inflation is the difference in yield between nominal and real rates (of the same issuer and maturity) and reflects the market's expectations of inflation over a given maturity. An implicit inflation position corresponds to holding an inflation-indexed bond hedged at a nominal rate on the same maturity and the same issuer, or through an identical strategy using inflation-linked derivatives.
Your fund seeks to benefit from the expected increase in inflation. On the other hand, if expected inflation (implicit inflation) drops in the markets, this will lead to a fall in net asset value, which will be all the more pronounced as sensitivity to implicit inflation is high. The choice of allocation of inflation exposures by geographical area and maturity will be based on the management team's market forecasts and technical criteria.

The Fund invests in fixed income products, in particular inflation-indexed bonds issued or guaranteed by OECD countries, denominated in the currencies of OECD countries, of any maturity and in government securities from the Eurozone and/or the United States denominated in euro or US dollars. The Fund will hold securities belonging to the "Investment Grade" category at the time of their acquisition, i.e. with ratings of BBB- [Source: S&P/Fitch] or Baa3 [Source: Moody's] or equivalent according to the criteria of the Management Company. For the credit category and risk assessment, the Management Company relies on its teams and its own methodology which includes, among other factors, the ratings issued by the main rating agencies.
Currency risk against the euro will be systematically hedged.
The level of exposure of the portfolio to inflation and the distribution of the portfolio by geographical area and by maturity segment may deviate from that of the benchmark.
The sensitivity of the portfolio, an indicator that measures the impact of interest rate changes on performance, is between [-2;+2].
Eligible forward financial instruments or temporary purchases and sales of securities may be used for hedging and/or exposure purposes.

The Fund is actively managed and aims to outperform its benchmark. Its management is discretionary: it is primarily exposed to issuers from the benchmark and may be exposed to issuers that are not included in this index. The management strategy includes monitoring the difference in the level of risk of the portfolio compared with that of the index. A moderate difference compared with the level of risk of this index is anticipated.
The benchmark is available at the website https://ihsmarkit.com

The Fund is subject to sustainability risk within the meaning of Regulation (EU) 2019/2088 on sustainability-related disclosures in the financial services sector (the "Disclosure Regulation") as defined in the risk profile of the prospectus.

**Intended retail investors:** This product is intended for investors with a basic knowledge and/or no or limited experience of investing in funds, who are seeking to increase the value of their investment over the recommended holding period and who are able to bear a loss of up to the full amount invested.
The product is not open to residents of the United States of America/"U.S. Person" (the definition of "U.S. Person" is available on the Management Company's website www.cpram.com and/or in the prospectus).

**Redemption and transaction:** Units may be sold (redeemed) daily as stated in the prospectus at the respective dealing price (net asset value). Further details are provided in the CPR Focus Inflation prospectus.

**Distribution Policy:** As this is a non-distributing unit class, investment income is reinvested.

**More information**: Further information regarding this product, including the prospectus and financial reports, is available free of charge on request from: CPR Asset Management – 91–93, boulevard Pasteur – CS 61595 – 75730 Paris Cedex 15.
The net asset value of the product is available at www.cpram.com

**Depositary:** CACEIS Bank.

## What are the risks and what could I get in return?

### RISK INDICATOR

1 **2** 3 4 5 6 7

Lowest risk — Highest risk

The risk indicator assumes you keep the product for three years.

The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movement in the markets or because we are not able to pay you.

We have classified this product as 2 out of 7, which is a low risk class. This rates the potential losses from future performance at a low level, and poor market conditions are very unlikely to impact our capacity to pay you.

**Additional risks**: Market liquidity risk could amplify the variation of product performances.
The use of complex products such as derivatives can lead to increased movement of securities in your portfolio.

This product does not include any protection from future market performance so you could lose some or all of your investment.

Beside the risks included in the risk indicator, other risks may affect the Fund's performance. Please refer to the CPR Focus Inflation prospectus.

## PERFORMANCE SCENARIOS

The unfavourable, moderate, and favourable scenarios shown are illustrations using the worst, average, and best performance of the Fund over the last 10 years. Markets could develop very differently in the future. The stress scenario shows what you might get back in extreme market circumstances.

**What you get from this product depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted.**

| Recommended holding period: 3 years<br>Investment EUR 10,000 | | | |
|---|---|---|---|
| **Scenarios** | | **If you exit after** | |
| | | **1 year** | **3 years** |
| **Minimum** | There is no minimum guaranteed return. You could lose some or all of your investment. | | |
| **Stress Scenario** | **What you might get back after costs** | €7,820 | €7,980 |
| | Average return each year | -21.8% | -7.2% |
| **Unfavourable Scenario** | **What you might get back after costs** | €8,760 | €8,110 |
| | Average return each year | -12.4% | -6.7% |
| **Moderate Scenario** | **What you might get back after costs** | €9,980 | €10,550 |
| | Average return each year | -0.2% | 1.8% |
| **Favourable Scenario** | **What you might get back after costs** | €11,260 | €12,600 |
| | Average return each year | 12.6% | 8.0% |

The figures shown include all the costs of the product itself, but may or may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back.

Unfavourable Scenario: This type of scenario occurred for an investment made between 31/03/2017 and 31/03/2020.
Moderate scenario: This type of scenario occurred for an investment made between 31/05/2023 and 29/05/2026.
Favourable scenario: This type of scenario occurred for an investment made between 31/03/2020 and 31/03/2023

## What happens if CPR Asset Management is unable to pay out?

The product is a co-ownership of financial instruments and deposits separate from the Management Company. In the event of default by the Management Company, the assets of the product held by the depositary will not be affected. In the event of default by the depositary, the risk of financial loss to the product is mitigated due to the legal segregation of the depositary's assets from those of the product.

## What are the costs?

The person advising on or selling you this product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.

### COSTS OVER TIME

The tables show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest, how long you hold the product, and how well the product does. The amounts shown here are illustrations based on an example investment amount and different possible investment periods.
We have assumed:
- in the first year you would get back the amount that you invested (0% annual return). For the other holding periods we have assumed the product performs as shown in the moderate scenario.
- EUR 10,000 invested.

| Investment EUR 10,000 | | |
|---|---|---|
| Scenarios | If you exit after | |
| | 1 year | 3 years* |
| Total costs | €168 | €320 |
| Annual Cost Impact** | 1.7% | 1.0% |

* Recommended holding period.
** This illustrates how costs reduce your return each year over the holding period. For example, it shows that if you exit at the recommended holding period, your average return per year is projected to be 2.85% before costs and 1.80% after costs.
These figures include the maximum distribution fee that the person selling you the product may charge (1.00% of amount invested/EUR 100). This person will inform you of the actual distribution fee.

## COMPOSITION OF COSTS

| | One-off costs upon entry or exit | If you exit after 1 year |
|---|---|---|
| Entry costs | This includes distribution costs of 1.00% of the amount invested. This is the most you will be charged. The person selling you the product will inform you of the actual charge. | Up to EUR 100 |
| Exit costs | We do not charge an exit fee for this product, but the person selling you the product may do so. | EUR 0.00 |
| | **Ongoing costs taken each year** | |
| Management fees and other administrative or operating costs | 0.63% of the value of your investment per year. This percentage is based on the actual costs over the last year. | EUR 61.97 |
| Transaction costs | 0.07% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the underlying investments for the product. The actual amount will vary depending on the volume of our purchases and sales. | EUR 6.66 |
| | **Incidental costs taken under specific conditions** | |
| Performance fees | 20.00% of the annual outperformance of the reference asset 100% 50% IBOXX USD BREAKEVEN 10-YEAR INFLATION + 50% IBOXX EUR BREAKEVEN 10-YEAR INFLATION FRANCE & GERMANY NR Close. The calculation applies on each Net Asset Value calculation date in accordance with the terms described in the prospectus. Past underperformances over the last five years must be recovered before any new performance fee accrual. The actual amount will vary depending on how well your investment performs. The aforementioned estimate of total costs includes the average over the past five years. **The performance fee is paid even if the performance of the unit over the observation period is negative, while remaining higher than the performance of the Reference Asset.** | EUR 0.00 |

## How long should I hold it and can I take money out early?

**Recommended holding period:** 3 years. This period is based on our assessment of the risk and reward characteristics and costs of the Fund. This product is designed for medium-term investment; you should be prepared to stay invested for at least 3 years. You can redeem your investment at any time, or hold the investment longer.

**Order schedule:** Redemption orders must be received before 12:00 (Paris time) on the net asset value calculation date. Please refer to the CPR Focus Inflation prospectus for more information about redemptions.

In order to manage liquidity risks, if redemption requests exceed a predefined threshold, the Management Company may cap redemptions (using what are known as "Gates") and only partially process such requests on a pro rata basis.

In order to promote a fair distribution of portfolio adjustment costs, the Management Company may use a predetermined net asset value adjustment mechanism by applying a factor reflecting the cost of liquidity (known as "Swing Pricing").
The ways in which these mechanisms operate is described in the prospectus.

## How can I complain?

If you have any complaints, you may:
- Mail CPR Asset Management at 91-93 boulevard Pasteur, 75015 Paris, France
- E-mail client.servicing@cpram.com

In the case of a complaint you must clearly indicate your contact details (name, address, phone number or email address) and provide a brief explanation of your complaint. More information is available on our website www.cpram.com.
If you have a complaint about the person that advised you about this product, or who sold it to you, they will tell you where to complain.

## Other relevant information

You may find the prospectus, statutes, key investor documents, notices to investors, financial reports, and further information documents relating to the Fund including various published policies of the Fund on our website www.cpram.com. You may also request a copy of such documents at the registered office of the Management Company.

When this product is used as a unit-linked vehicle in a life insurance or capitalisation contract, additional information about this contract, such as the costs of the contract, which are not included in the costs mentioned in this document, the contact details for complaints and the procedures in the event of default of the insurance company are provided in the key information document of the contract, which must be provided to you by your insurer or broker or any other insurance intermediary in compliance with their legal obligation.
Past performance: You can download the past performance of the Fund over the last ten years at www.cpram.com.
Performance scenarios: You can find previous performance scenarios updated on a monthly basis at www.cpram.com.